CROMSOURCE, an international full service contract research organization (CRO), today announced the official opening of new office premises in Paris, France.
CROMSOURCE, an international full service contract research organization (CRO), today announced the official opening of new office premises in Paris, France.
‘CROMSOURCE continues to grow successfully as a result of our unique commitment to deliver our clients’ projects on time, on budget and to the highest quality’, noted Oriana Zerbini, CEO of CROMSOURCE. ‘As a result we needed to increase our presence in France, and I am delighted to announce that we have done this through expansion of our team and the opening of new office premises.’
‘With more than 33% of international phase II and III studies being performed here, France is a key strategic country for CROMSOURCE’, said Christian Milla, Global Head of the Medical Division and Director of Operations, France. Christian is based in the new offices, which are located on the Left Bank area of Paris, close to the University of Sciences and the Paris Biopark. ‘We have been growing our activity here year on year, and we look forward to further growth in this region in years to come. With our intense client focus, comprehensive service portfolio and international reach we are a perfect development partner for the vibrant life sciences industry in France. Being on the French Ministry of Research (FMR) list of approved CROs also means that many of our clients can claim significant tax credits for R&D activities executed by CROMSOURCE on their behalf.’
Margherita Mosconi, Director of Client Project Development, added ‘There is a high demand in France from smaller biopharmaceutical and medical technology companies for knowledgeable partners who can support them and keep within timelines and budgets. These clients appreciate the CROMSOURCE philosophy of acting as an expert addition to their team. We leverage our expertise to propose the optimal approach to each of their projects. Uniquely, we then guarantee to deliver the plan to the highest quality, on time and on budget.’
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.